Report from the extra general meeting
At the extra general meeting (EGM) of ChronTech Pharma AB (below ”the Company”) on the 6th of May, 2013 it was resolved to reduce the share capital by means of redemption and cancellation of shares and to amend the articles of association. The resolution means that the share capital will be reduced by SEK 2,408,228.85 to cover losses by means of redemption and cancellation of 80,274,295 shares. The shares that will be redeemed and cancelled are owned by the group of shareholders that will buy approximately 70 per cent of the Company’s project regarding development of DNA vaccines against